Akeega Patient MOA

On the job against prostate cancer

Men with BRCA-mutated prostate cancer struggle to understand the science behind their aggressive disease, and understand Akeega’s dual-action approach to treating it even less.

But then they see the factory: A BRCA-mutated cell starting to crank out cancer. With manly machinery as our metaphor, we show how hard-working PARP and Testosterone end up creating and accelerating the disease.

That is, until help arrives in the form Akeega’s dual-action duo (niraparib and abiraterone acetate), who heroically insert themselves in the process and shut cancer production down.

For patients desperate for clarity, Akeega on the Job turns complex science into something they can grasp and believe in.